A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
← catalyst calendarNCT06897930 · readout in 986 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
20
Countries
Australia, Canada, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-21 | actual | When the study began enrolling |
| Primary completion | 2029-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lupus Erythematosus, Systemic
Interventions
- Biological: AZD0120 — also filed as GC012F
- Drug: Cyclophosphamide
- Drug: Fludarabine
Primary outcomes
what the primary-completion date above is the date OFPHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)
measured 2 years
PHASE 1B: Recommended Phase 2 Dose (RP2D) of AZD0120 in for Phase 2
measured 2 years
PHASE 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
measured 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed